The Impact of the US Executive Order on Drug Pricing on Chinese Companies

Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model

By Xiangxiang Ma

The Impact of the US Executive Order on Drug Pricing on Chinese Companies

Summary

U.S. President Donald Trump’s recent executive order on drug pricing is built around a Most Favored Nation pricing policy

China’s pharmaceutical industry has evolved from primarily a license-in industry to one which is focused on licensing-out.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)